In this free webinar, gain insights into the latest guidelines from the FDA and EMA on drug labeling in clinical pharmacology. Attendees will gain insights into how recent updates in regulatory guidance have affected drug-labeling studies. Attendees will learn which scenario for scheduling drug-labeling studies they should choose. The featured speakers will discuss the options when designing drug-labeling studies.
TORONTO, Oct. 10, 2023 /PRNewswire-PRWeb/ -- During clinical development, new drug candidates undergo a series of key studies aiming to establish optimal treatment doses and dosing regimens and to confirm drug efficacy. Accompanying these principle clinical trials, a variety of ancillary studies — often referred to as drug labeling or new drug application (NDA) enabling studies — need to be conducted to complete a drug's filing dossier as a prerequisite for initiating the drug approval process. Common examples of drug labeling studies are: food effect studies, drug-drug interaction (DDI) studies, cardiac safety (QTc assessment or thorough QT [TQT]) studies, absorption-distribution-metabolism-excretion (ADME) studies, ethnic bridging studies and studies in special populations such as renally or hepatically impaired patients, elderly and postmenopausal subjects.
In practice, some of the above mentioned studies are integrated in the early stage of clinical development in healthy volunteers. For instance, food effect can be added to first-in-human, single and multiple ascending dose studies as a separate treatment arm. Robust QTc assessment can also be incorporated into multiple ascending dose studies to assess a drug's proarrhythmic potential, while TQT studies are typically stand-alone trials that may be initiated at a later stage.
Although the scenarios for embedding labeling studies in the clinical development program may depend on prioritization, budgets and sheer practicalities, drug development usually benefits from setting up a well-balanced strategy early on during drug development.
Over the past three years, the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) have issued either final guidance or updated guidelines for food effect, DDI, ADME, TQT and renal impairment studies. This webinar will summarize these key guidance documents and highlight recent changes drug developers need to know.
From the perspective of current regulatory guidance, this webinar will consider the setup and conduct of selected labeling studies, strategic aspects and best practices.
Join this webinar to gain insights into the latest guidelines from the FDA and EMA on drug labeling in clinical pharmacology.
Join experts from Celerion, Aernout van Haarst, PhD, Director of Scientific Affairs; and Sabina Paglialunga, PhD, Director of Scientific Affairs, for the live webinar on Tuesday, October 24, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com
SOURCE Xtalks
